

**Imfinzi® (durvalumab) Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_

**Drug Information**

**Physician billing (HCPCS code:** \_\_\_\_\_ **) Start Date (or date of next dose):** \_\_\_\_\_

**Dose:** \_\_\_\_\_ **Dosing Regimen:** \_\_\_\_\_

**Billing Provider Information**

**Provider NPI:** \_\_\_\_\_ **Provider Name:** \_\_\_\_\_

**Provider Phone:** \_\_\_\_\_ **Provider Fax:** \_\_\_\_\_

**Prescriber Information**

**Prescriber NPI:** \_\_\_\_\_ **Prescriber Name:** \_\_\_\_\_

**Prescriber Phone:** \_\_\_\_\_ **Prescriber Fax:** \_\_\_\_\_ **Specialty:** \_\_\_\_\_

**Criteria**

**For Initial Authorization (Initial approval will be for the duration of 6 months):**

1. Please indicate the diagnosis and information:

**Non-Small Cell Lung Cancer (NSCLC)**

- A. Does member have resectable (tumors ≥4cm and/or node positive) NSCLC? Yes \_\_\_ No \_\_\_
  - i. If yes, will durvalumab be used in combination with platinum-containing chemotherapy as neoadjuvant treatment before surgery, followed by single agent durvalumab as adjuvant treatment after surgery? Yes \_\_\_ No \_\_\_
  - ii. Are there any epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements? Yes \_\_\_ No \_\_\_
- B. Does member have unresectable stage II or III NSCLC? Yes \_\_\_ No \_\_\_
  - i. If yes, has member's disease progressed following concurrent platinum-based chemotherapy and radiation therapy? Yes \_\_\_ No \_\_\_
- C. Does member have metastatic NSCLC? Yes \_\_\_ No \_\_\_
  - i. If yes, does member have an epidermal growth factor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations? Yes \_\_\_ No \_\_\_
  - ii. Will durvalumab be used in conjunction with Imjudo® (tremelimumab-actl) and platinum-based chemotherapy? Yes \_\_\_ No \_\_\_

**Extensive-Stage Small Cell Lung Cancer (ES-SCLC)**

- A. Will durvalumab be used in combination with etoposide and either cisplatin or carboplatin followed by single-agent maintenance? Yes \_\_\_ No \_\_\_

**Limited-Stage Small Cell Lung Cancer (LS-SCLC)**

- A. Has disease progressed following concurrent platinum-based chemotherapy and radiation therapy? Yes \_\_\_ No \_\_\_
- B. Will durvalumab be used as a single agent? Yes \_\_\_ No \_\_\_

**(Page 1 of 2)**

<p><u>PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:</u></p> <p style="text-align: center;">University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit</p> <p style="text-align: center;">Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4</p>	<p style="text-align: center;"><u>CONFIDENTIALITY NOTICE</u></p> <p><i>This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.</i></p>
--	--

**Imfinzi® (durvalumab) Prior Authorization Form**

**Member Name:** \_\_\_\_\_ **Date of Birth:** \_\_\_\_\_ **Member ID#:** \_\_\_\_\_

**Criteria**

**For Initial Authorization:**

1. Please indicate the diagnosis and information: *(continued)*

**Bladder Cancer**

- A. Is diagnosis muscle invasive bladder cancer? Yes \_\_\_ No \_\_\_
- B. Will durvalumab be used in combination with gemcitabine and cisplatin as neoadjuvant treatment for 4 cycles? Yes \_\_\_ No \_\_\_
- C. Will durvalumab be followed by single-agent adjuvant treatment following radical cystectomy for up to 8 additional cycles? Yes \_\_\_ No \_\_\_

**Hepatocellular Carcinoma (HCC)**

- A. Does member have a diagnosis of unresectable HCC? Yes \_\_\_ No \_\_\_
- B. Will durvalumab be used in combination with Imjudo® (tremelimumab-actl)? Yes \_\_\_ No \_\_\_
- C. Will durvalumab be used as a single agent? Yes \_\_\_ No \_\_\_

**Endometrial Cancer**

- A. Is diagnosis primary advanced (FIGO measurable stage III/newly diagnosed stage IV) or recurrent endometrial cancer? Yes \_\_\_ No \_\_\_
- B. Mismatch repair deficient (dMMR)? Yes \_\_\_ No \_\_\_
- C. Will durvalumab be used in combination with carboplatin and paclitaxel followed by single-agent maintenance? Yes \_\_\_ No \_\_\_

**Biliary Tract Cancer**

- A. Does member have locally advanced or metastatic biliary tract cancer? Yes \_\_\_ No \_\_\_
- B. Will durvalumab be used in combination with gemcitabine and cisplatin? Yes \_\_\_ No \_\_\_

**Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma**

- A. Is disease resectable? Yes \_\_\_ No \_\_\_
- B. Is disease positive for programmed death ligand 1 (PD-L1) with a combined positive score (CPS)  $\geq 1$  or tumor area positivity (TAP)  $\geq 1\%$ ? Yes \_\_\_ No \_\_\_
- C. Will durvalumab be used in combination with fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) chemotherapy as neoadjuvant and adjuvant treatment? Yes \_\_\_ No \_\_\_
- D. Will durvalumab be used as single agent maintenance therapy following combination therapy with FLOT chemotherapy? Yes \_\_\_ No \_\_\_

**For Continued Authorization:**

- 1. Date of last dose: \_\_\_\_\_
- 2. Does member have any evidence of progressive disease while on durvalumab? Yes \_\_\_ No \_\_\_
- 3. Has the member experienced adverse drug reactions related to durvalumab therapy? Yes \_\_\_ No \_\_\_

*If yes, please specify adverse reactions:* \_\_\_\_\_

**(Page 2 of 2)**

**Prescriber Signature:** \_\_\_\_\_ **Date:** \_\_\_\_\_

**I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge. Failure to complete this form in full will result in processing delays.**

<p><u>PLEASE PROVIDE THE INFORMATION REQUESTED AND RETURN TO:</u></p> <p>University of Oklahoma College of Pharmacy Pharmacy Management Consultants Product Based Prior Authorization Unit</p> <p>Fax: 1-800-224-4014 Phone: 1-800-522-0114 Option 4</p>	<p><u>CONFIDENTIALITY NOTICE</u></p> <p><i>This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.</i></p>
--	--